- Home
- NPT vs XGN Comparison
NPT vs XGN Comparison
Compare NPT & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NPT | XGN |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 110.8M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NPT | XGN |
|---|---|---|
| Price | $5.90 | $3.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.9M | 586.0K |
| Earning Date | 02-27-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $797,148,640.00 | $63,599,000.00 |
| Revenue This Year | N/A | $21.40 |
| Revenue Next Year | N/A | $14.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.51 | 14.08 |
| 52 Week Low | $3.14 | $2.67 |
| 52 Week High | $13.48 | $12.23 |
Technical Indicators
Market Signals| Indicator | NPT | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 48.86 | 26.27 |
| Support Level | $5.90 | $3.18 |
| Resistance Level | $7.00 | $3.69 |
| Average True Range (ATR) | 1.56 | 0.29 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 10.64 | 11.07 |
Price Performance
Historical ComparisonAbout NPT Texxon Holding Limited Ordinary shares
Texxon Holding Ltd provides technology-enabled supply chain management services to customers in the plastics and chemical industries in East China. The company operates through two segments: Supply Chain Trading and Plastic Manufacturing. Its services include procurement, logistics, payments, and fulfillment for Chinese SMEs, and all revenue is generated from operations within the People's Republic of China.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.